MIB Agents OsteoBites and osTEAo

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.

Matteo Trucco, MD is Director Children's Cancer Innovative Therapy Program Associate Staff, Peds Hematology-Oncology & BMT at Cleveland Clinic. He received his training in Pediatric Hematology/Oncology from John's Hopkins and the National Cancer Institute and has focused his career primarily on Pediatric Sarcomas and the development of new therapies.

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.

With almost 25 years of experience as a registered dietitian nutritionist, Natalie is a well-seasoned practitioner. A board-certified specialist in oncology nutrition, Natalie is the founding dietitian for the nutrition program at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center and is the clinical nutrition specialist at Smith Integrative Oncology in San Francisco. On a daily basis, she works with patients through her integrative & functional nutrition private practice.

Natalie serves as a consultant and speaker for Digestive Care, Inc. and Kate Farms. As a member of the Lilly Lecture Bureau Faculty, Natalie regularly presents to health care practitioners on Nutritional Counseling in Oncology Care. She is a certified LEAP therapist who helps manage adverse food reactions with an emphasis on food sensitivities. Natalie provides nutrition counseling and frequently presents nationally on various cancer and integrative health focused nutrition topics. She has taught college courses and cooking classes, and has been extensively involved in community outreach.

Natalie is highly regarded in her industry and is often sought out for her expert opinion. She has been interviewed by The New York Times, NBC, Fortune magazine, Cure magazine, MAMM magazine, Runner’s World, and the San Francisco Chronicle. Recent publications include Oncology Nutrition for Clinical Practice (co-editor and author), Health & Wellness: Living with Prostate Cancer for the Prostate Cancer Foundation, and nutrition chapters in Clinical Nutrition for Oncology Patients, Everyone’s Guide to Cancer Therapy, Everyone’s Guide to Cancer Survivorship, Nutritional Issues in Cancer Care, and Supportive Cancer Care: The Complete Guide for Patients and their Families.

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Their drug, Voraxaze, is for high-dose methotrexate toxicity.

Dr. Weiss is a Founding Member of the Musculoskeletal Oncology Research Initiative (MORI), Pittsburgh Cure Sarcoma (PCS), the Pittsburgh Sarcoma Research Collaborative (PSaRC), and the Pittsburgh Center for Bone and Mineral Research (PCBMR). He is a peer reviewer for multiple journals including the Journal of the American Academy of Orthopaedic Surgeons, BioMed Central Cancer, Sarcoma, Cancer Research, International Journal of Cancer, and others. He is a former member of the NIH’s Center for Scientific Review Early Career Reviewer program. He has served on multiple National Cancer Institute Study Sections. He is a member of the Musculoskeletal Tumor Society (MSTS) for which he serves as Chair of the Research Committee and the Connective Tissue Oncology Society (CTOS), for which he has served on the Board of Directors.

Kara Skrubis and was diagnosed with osteosarcoma in January of 2020. Kara received 9 months of chemotherapy, a left above the knee amputation, and then 8 months of immunotherapy. Currently, Kara is 20 years old living in Buffalo, New York attending the University at Buffalo pursuing a child life certification. In her free time Kara enjoys dancing, art, fostering dogs, photography, and her work with the MIB Junior Advisory Board serving as the 2022 president!

Dr. John Doski, a pediatric surgeon from the UT Health San Antonio will discuss an upcoming randomized trial comparing open and minimally invasive thorascopic surgery for pulmonary metastatic osteosarcoma.

Today we talk with Dr. Damon Reed from Moffit Cancer Center and Dr. Nicola Mason from  University of Pennsylvania School of Veterinary Medicine about the promising results from a multi-institutional clinical trial evaluating the safety and efficacy of a recombinant Listeria to prevent metastatic disease in dogs with osteosarcoma, and how that will translate to a human trial.   #clinicaltrials #osteosarcoma #cancerupdates

In this weeks Osteobites episode Dr. Pete Anderson of Cleveland Clinic, together with OsteoWarriors Andrew, Kara, and Mia, will be asking and answering your questions about Osteosarcoma.

IIn this weeks Ostoebites episode we chat with Dr. Valerae Lewis & Elise Robinson Rotationplasty and back to activity!  

Elise Robinson is 15 years old, an osteosarcoma survivor, MIB Agents Ambassador Agent, and MIB Agents Junior Board member. Elise was diagnosed with osteosarcoma in 2014 when she was eight years old. Elise is active in sports and brings awareness to childhood cancer, osteosarcoma, and amputees with her active lifestyle.  

Valerae O. Lewis, M.D.  Professor, Orthopaedic Oncology, Division of Surgery  Chair, Department of Orthopaedic Oncology, Division of Surgery  Dr. John Murray Professor in Orthopaedic Oncology  The University of Texas M. D. Anderson Cancer Center   Dr. Lewis, the John Murray Professor of Orthopaedic Oncology, attended Yale University and matriculated at Harvard Medical School, graduating with honors. She completed her Orthopaedic training at the Harvard Combined Orthopaedic Residency Program in Boston, MA and her fellowship in Musculoskeletal Oncology at the University of Chicago. The first African American woman to be awarded the MD Anderson Faculty Achievement Award in Patient Care she is now the Chair of the Department of Orthopaedic Oncology at MD Anderson.   

Dr. Lewis is very active nationally and internationally within Orthopaedics and Musculoskeletal Oncology. She is a strong advocate of education, and as such, served as the Chair of the Musculoskeletal Tumor Society (MSTS) Education Committee, Chair of the American Academy of Orthopaedic Surgery (AAOS) Instructional Course Lecture Tumor Subcommittee, Chair of the Musculoskeletal Oncology Content Committee for the AAOS Council on Education and Chair of the International Society of Limb Salvage (ISOLS) Education Committee. A former board member of the American Orthopaedic Association, the Western Orthopaedic Association, MSTS and the ISOLS, she was recently elected to the Board of Directors of the AAOS   Dr. Lewis’ area of expertise is in the treatment of both children and adults with bone and soft tissue sarcomas. Her clinical research focuses on the outcome of patients after hemipelvectomy surgery and her lab investigates the gene functions tied to osteosarcoma and the development of treatments that might interrupt this process. Married for 27 years, Dr. Lewis is the mother of two wonderful 18-year-old twins.   

What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts Bereaved Parent Support ✨ Ambassador Agents - Peer Support EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: ✨ Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org​ Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Join Dr Filemon Dela Cruz & Dr. Julia Glade Bender as they talk about The OLIE Study - Evaluating lenvatinib in combination with chemotherapy for relapsed or refractory osteosarcoma.  

MIB Agents Osteosarcoma Webinar Series:  Alanna Church, MD of Boston Children's and Harvard Medical School and Christina Ip-Toma, MIB Scientific Advisory Board Member and lead of the MIB Testing & Research Directory, talk about navigating the Testing & Research Directory to help inform a personal treatment plan or to inform research.  

Christina Ip-Toma, Osteomom, and Alanna Church, MD Pathologist at Dana Farber & Harvard Medical School, worked together with Matteo Trucco, MD, Katie Janeway, MD, Alejandro Sweet-Cordero, MD, Will Parsons, MD, Joshua Schiffman, MD, Ines Lohse, PhD and Al Cornelius, MD to bring the Testing & Research Directory to you as an essential decision-making document. 

Guest Information: 

Alanna Church, MD is the Associate Director for Molecular Pediatric Pathology Laboratory (LaMPP) Staff Pathologist, Department of Pathology Boston Children's Hospital Assistant Professor of Pathology Harvard Medical School  

Christina Ip-Toma is an MIB Agents Scientific Advisory Board Member, Lead of the MIB Agents Testing & Research Directory, and OsteoMom to Dylan

Osteobites: Junior Board, Like No One is Listening